Outcomes of Surgical Aortic Valve Replacement: The Benchmark for Percutaneous Therapies

Pietro Bajona, Rakesh M. Suri, Kevin L. Greason, Hartzell V Schaff

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Historically, many patients with severe senile calcific aortic valve stenosis (AS) were not offered surgery, largely due to the perception that the risks of operation were prohibitive. Such patients have subsequently been formally designated as 'high risk' or 'inoperable' with respect to their suitability for surgical aortic valve replacement (SAVR) in the evolving lexicon of heart valve disease. The recent availability of transcatheter aortic valve replacement (TAVR) represents an alternative treatment option, and permits the opportunity to re-examine algorithms for assessing operative risk. As the experience with TAVR grows, expanded use in new patient populations can be anticipated. While TAVR in high risk AS patients has demonstrated benefits, the emerging indication in intermediate AS is less clear and conclusions will necessarily await the availability of results from ongoing clinical trials. This article will discuss current outcomes for SAVR among high- and intermediate-risk patients with AS as a barometer in assessing the results of nascent percutaneous therapies.

Original languageEnglish (US)
Pages (from-to)619-624
Number of pages6
JournalProgress in Cardiovascular Diseases
Volume56
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Benchmarking
Aortic Valve
Surgical Instruments
Aortic Valve Stenosis
Therapeutics
Heart Valve Diseases
Clinical Trials
Population
Transcatheter Aortic Valve Replacement

Keywords

  • Aortic stenosis
  • Aortic valve replacement
  • Surgery
  • Transcatheter aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes of Surgical Aortic Valve Replacement : The Benchmark for Percutaneous Therapies. / Bajona, Pietro; Suri, Rakesh M.; Greason, Kevin L.; Schaff, Hartzell V.

In: Progress in Cardiovascular Diseases, Vol. 56, No. 6, 2014, p. 619-624.

Research output: Contribution to journalArticle

Bajona, Pietro ; Suri, Rakesh M. ; Greason, Kevin L. ; Schaff, Hartzell V. / Outcomes of Surgical Aortic Valve Replacement : The Benchmark for Percutaneous Therapies. In: Progress in Cardiovascular Diseases. 2014 ; Vol. 56, No. 6. pp. 619-624.
@article{72025f98f2944835aa9a9d315ff0a830,
title = "Outcomes of Surgical Aortic Valve Replacement: The Benchmark for Percutaneous Therapies",
abstract = "Historically, many patients with severe senile calcific aortic valve stenosis (AS) were not offered surgery, largely due to the perception that the risks of operation were prohibitive. Such patients have subsequently been formally designated as 'high risk' or 'inoperable' with respect to their suitability for surgical aortic valve replacement (SAVR) in the evolving lexicon of heart valve disease. The recent availability of transcatheter aortic valve replacement (TAVR) represents an alternative treatment option, and permits the opportunity to re-examine algorithms for assessing operative risk. As the experience with TAVR grows, expanded use in new patient populations can be anticipated. While TAVR in high risk AS patients has demonstrated benefits, the emerging indication in intermediate AS is less clear and conclusions will necessarily await the availability of results from ongoing clinical trials. This article will discuss current outcomes for SAVR among high- and intermediate-risk patients with AS as a barometer in assessing the results of nascent percutaneous therapies.",
keywords = "Aortic stenosis, Aortic valve replacement, Surgery, Transcatheter aortic valve replacement",
author = "Pietro Bajona and Suri, {Rakesh M.} and Greason, {Kevin L.} and Schaff, {Hartzell V}",
year = "2014",
doi = "10.1016/j.pcad.2014.02.004",
language = "English (US)",
volume = "56",
pages = "619--624",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Outcomes of Surgical Aortic Valve Replacement

T2 - The Benchmark for Percutaneous Therapies

AU - Bajona, Pietro

AU - Suri, Rakesh M.

AU - Greason, Kevin L.

AU - Schaff, Hartzell V

PY - 2014

Y1 - 2014

N2 - Historically, many patients with severe senile calcific aortic valve stenosis (AS) were not offered surgery, largely due to the perception that the risks of operation were prohibitive. Such patients have subsequently been formally designated as 'high risk' or 'inoperable' with respect to their suitability for surgical aortic valve replacement (SAVR) in the evolving lexicon of heart valve disease. The recent availability of transcatheter aortic valve replacement (TAVR) represents an alternative treatment option, and permits the opportunity to re-examine algorithms for assessing operative risk. As the experience with TAVR grows, expanded use in new patient populations can be anticipated. While TAVR in high risk AS patients has demonstrated benefits, the emerging indication in intermediate AS is less clear and conclusions will necessarily await the availability of results from ongoing clinical trials. This article will discuss current outcomes for SAVR among high- and intermediate-risk patients with AS as a barometer in assessing the results of nascent percutaneous therapies.

AB - Historically, many patients with severe senile calcific aortic valve stenosis (AS) were not offered surgery, largely due to the perception that the risks of operation were prohibitive. Such patients have subsequently been formally designated as 'high risk' or 'inoperable' with respect to their suitability for surgical aortic valve replacement (SAVR) in the evolving lexicon of heart valve disease. The recent availability of transcatheter aortic valve replacement (TAVR) represents an alternative treatment option, and permits the opportunity to re-examine algorithms for assessing operative risk. As the experience with TAVR grows, expanded use in new patient populations can be anticipated. While TAVR in high risk AS patients has demonstrated benefits, the emerging indication in intermediate AS is less clear and conclusions will necessarily await the availability of results from ongoing clinical trials. This article will discuss current outcomes for SAVR among high- and intermediate-risk patients with AS as a barometer in assessing the results of nascent percutaneous therapies.

KW - Aortic stenosis

KW - Aortic valve replacement

KW - Surgery

KW - Transcatheter aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=84900017484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900017484&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2014.02.004

DO - 10.1016/j.pcad.2014.02.004

M3 - Article

C2 - 24838137

AN - SCOPUS:84900017484

VL - 56

SP - 619

EP - 624

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 6

ER -